Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study-Reference-Cited by-同舟云学术

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study

Published:2019-07-08 Issue:3 Volume:39 Page:252-255
ISSN:2574-173X
Container-title:Neuropsychopharmacology Reports
language:en
Short-container-title:Neuropsychopharmacol Rep

Author:

Kishi Taro¹^ORCID,Sakuma Kenji¹,Okuya Makoto¹,Ninomiya Kohei¹,Oya Kazuto¹,Kubo Momoko¹²,Matsui Yuki¹³,Nomura Ikuo¹⁴,Okuyama Yuji¹⁴,Matsunaga Shinji¹⁵,Iwata Nakao¹

Affiliation:

1. Department of Psychiatry Fujita Health University School of Medicine Toyoake Aichi Japan

2. Department of Psychiatry The Okehazama Hospital Toyoake Aichi Japan

3. Department of Psychiatry The Jindai Hospital Toyota Aichi Japan

4. Department of Psychiatry The Moriyama General Mental Hospital Nagoya Aichi Japan

5. Department of Geriatrics and Cognitive Disorders Fujita Health University School of Medicine Toyoake Aichi Japan

Funder

Fujita Health University

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Clinical Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/npr2.12069

Reference8 articles.

1. Sleep disturbance in schizophrenia

2. Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders

3. Sleep Disturbance in Bipolar Disorder: Therapeutic Implications

4. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

5. Insomnia Pharmacotherapy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review;Translational Psychiatry;2024-09-14

2. Insomnia and the Orexinergic Pathway in the Link with Psychopathology: Effects of DORAs in Insomnia Comorbid with Mental Disturbances;Current Sleep Medicine Reports;2024-04-18

3. Suvorexant improves mitochondrial dynamics with the regulation of orexinergic and mTOR activation in rats exhibiting PTSD-like symptoms;Journal of Affective Disorders;2024-04

4. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study;Advances in Therapy;2024-03-09

5. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities;Neuropharmacology;2024-03